PP1, PKA and DARPP-32 in breast cancer: A retrospective assessment of protein and mRNA expression.
Biomarkers, Tumor
/ genetics
Breast Neoplasms
/ genetics
Combined Modality Therapy
Cyclic AMP-Dependent Protein Kinases
/ genetics
Dopamine and cAMP-Regulated Phosphoprotein 32
/ genetics
Female
Gene Expression Regulation, Neoplastic
Humans
Middle Aged
Phosphorylation
Prognosis
Protein Phosphatase 1
/ genetics
Retrospective Studies
Survival Rate
DARPP-32
PKA
PP-1
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
22
02
2021
received:
11
12
2020
accepted:
24
02
2021
pubmed:
16
5
2021
medline:
1
10
2021
entrez:
15
5
2021
Statut:
ppublish
Résumé
Cyclic AMP-dependent protein kinase A (PKA) and protein phosphatase 1 (PP1) are proteins involved in numerous essential signalling pathways that modulate physiological and pathological functions. Both PP1 and PKA can be inhibited by dopamine- and cAMP-regulated phosphoprotein 32 kD (DARPP-32). Using immunohistochemistry, PKA and PP1 expression was determined in a large primary breast tumour cohort to evaluate associations between clinical outcome and clinicopathological criteria (n > 1100). In addition, mRNA expression of PKA and PP1 subunits was assessed in the METABRIC data set (n = 1980). Low protein expression of PKA was significantly associated with adverse survival of breast cancer patients; interestingly, this relationship was stronger in ER-positive breast cancer patients. PP1 protein expression was not associated with patient survival. PKA and PP1 subunit mRNA was also assessed; PPP1CA, PRKACG and PRKAR1B were associated with breast cancer-specific survival. In patients with high expression of DARPP-32, low expression of PP1 was associated with adverse survival when compared to high expression in the same group. PKA expression and PP1 expression are of significant interest in cancer as they are involved in a wide array of cellular processes, and these data indicate PKA and PP1 may play an important role in patient outcome.
Identifiants
pubmed: 33991172
doi: 10.1111/jcmm.16447
pmc: PMC8178272
doi:
Substances chimiques
Biomarkers, Tumor
0
Dopamine and cAMP-Regulated Phosphoprotein 32
0
Ppp1r1b protein, mouse
0
Cyclic AMP-Dependent Protein Kinases
EC 2.7.11.11
Protein Phosphatase 1
EC 3.1.3.16
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5015-5024Subventions
Organisme : University of Nottingham
Informations de copyright
© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Cancer Res. 2002 Jul 15;62(14):4061-4
pubmed: 12124342
Nature. 1999 Dec 9;402(6762):669-71
pubmed: 10604473
Oncotarget. 2017 Oct 26;8(62):105196-105210
pubmed: 29285244
BMC Cancer. 2007 May 19;7:85
pubmed: 17511879
Gastroenterology. 2020 Nov;159(5):1882-1897.e5
pubmed: 32768595
Oncogene. 2016 May;35(21):2777-88
pubmed: 26387546
Biomolecules. 2019 Feb 07;9(2):
pubmed: 30736436
Oncogene. 2015 Feb 26;34(9):1160-73
pubmed: 24662820
EBioMedicine. 2019 Oct;48:236-247
pubmed: 31521612
Cell Signal. 2017 Dec;40:53-61
pubmed: 28867659
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
J Cell Mol Med. 2021 Jun;25(11):5015-5024
pubmed: 33991172
Nature. 1984 Aug 9-15;310(5977):503-5
pubmed: 6087160
Br J Cancer. 2020 Sep;123(5):819-832
pubmed: 32499571
J Cell Mol Med. 2020 Jun;24(11):6263-6271
pubmed: 32352232
Oncogene. 2019 Jul;38(29):5805-5816
pubmed: 31235784
PLoS One. 2012;7(7):e40769
pubmed: 22815811
Commun Biol. 2018;1:43
pubmed: 29782621
Br J Cancer. 2005 Aug 22;93(4):387-91
pubmed: 16106245
Clin Cancer Res. 2009 Dec 1;15(23):7196-206
pubmed: 19920112
Clin Cancer Res. 2018 Mar 1;24(5):1216-1226
pubmed: 29180608
J Cell Mol Med. 2020 Aug;24(16):9165-9175
pubmed: 32588513
Oncotarget. 2017 Nov 20;8(63):106551-106564
pubmed: 29290970
J Cell Biol. 1998 Jun 1;141(5):1207-15
pubmed: 9606212
Clin Cancer Res. 2004 Nov 1;10(21):7252-9
pubmed: 15534099
Med Sci Monit. 2018 Oct 05;24:7100-7108
pubmed: 30289875
Nature. 1983 Jan 6;301(5895):69-71
pubmed: 6296685
Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):144-152
pubmed: 30026077
Oncogene. 2013 Jul 25;32(30):3543-51
pubmed: 22907427
Biochem Pharmacol. 2019 Feb;160:71-79
pubmed: 30552871
Cancer Cell. 2004 Jun;5(6):597-605
pubmed: 15193262